Sign inCreate account

Report workspace tools

NCT02299661COMPLETEDanonymous

An Open-Label, Randomised, Parallel Group Pilot Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single Doses of DS-1093a in Patients With Chronic Kidney Disease

Sponsor

Source record

Daiichi Sankyo

Phase

Source record

PHASE1

Modality

AI-normalized

small molecule

Target

AI-normalized

Hypoxia-inducible factor prolyl hydroxylases

Indication / condition

AI-normalized

Chronic Renal Disease

Intervention

Source record

DS-1093a

Source & freshness

Source record

NCT ID

NCT02299661

Original source

ClinicalTrials.gov

Source last updated

Dec 24, 2018

Ingested at

May 30, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT02299661

Title

An Open-Label, Randomised, Parallel Group Pilot Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single Doses of DS-1093a in Patients With Chronic Kidney Disease

Sponsor

Daiichi Sankyo

Status

COMPLETED

Phase

PHASE1

Condition raw

Chronic Renal Disease

Condition normalized

Chronic Renal Disease

Modality raw

Chronic Renal Disease

Modality normalized

small molecule

Target raw

Hypoxia-inducible factor prolyl hydroxylases

Target normalized

Hypoxia-inducible factor prolyl hydroxylases

Interventions

DS-1093a

Public preview

Source record

DS-1093a is a novel inhibitor designed to increase erythropoietin levels in patients with chronic kidney disease (CKD). The trial aimed to assess its pharmacokinetics, pharmacodynamics, safety, and tolerability in a small cohort of CKD patients, including those on hemodialysis.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

An Open-Label, Randomised, Parallel Group Pilot Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single Doses of DS-1093a in Patients With Chronic Kidney Disease

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT02299661

Status

COMPLETED

Phase

PHASE1

Sponsor

Daiichi Sankyo

Executive brief

Investment-Ready Snapshot

DS-1093a is a novel inhibitor designed to increase erythropoietin levels in patients with chronic kidney disease (CKD). The trial aimed to assess its pharmacokinetics, pharmacodynamics, safety, and tolerability in a small cohort of CKD patients, including those on hemodialysis.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedDec 24, 2018
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT02299661

Indication

Chronic Renal Disease

Modality

small molecule

Target

Hypoxia-inducible factor prolyl hydroxylases

Intervention

DS-1093a

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.